FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	VAL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response	0.5
	OMB Number: Estimated average bu

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Kesponse:	-,														
1. Name and Address of Reporting Person* RINGROSE PETER S				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/23/2012							Officer (give	e title below)	Oth	er (specify below	r)	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Tal	ble I -	Non-Deriv	ative Secur	ties Ac	cquired,	Disposed	of, or Bene	ficially Own	ed	
1.Title of S (Instr. 3)	1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		Executi any	. Deemed ecution Date, if y Ionth/Day/Year	if Co		(A	4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)					d	Ownership Form:	7. Nature of Indirect Beneficial Ownership	
						. ,	Code	e V A	mount (A)			(msu. 3 and 4)			or Indirect (I) (Instr. 4)	
Reminder:	Report on a s	separate line for each	relass of securities		ily own		,	Persons in this f	who resporm are no are not	t requ	ired to i	respond	unless the	tion contair e form	ed SEC 1	474 (9-02)
Reminder:	Report on a s	separate line for each	relass of securities		ily Own	<u> </u>	,	Persons in this f	orm are no	t requ	ired to i	respond	unless the		ed SEC 1	474 (9-02)
1. Title of	2. Conversion	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., pu 4. Transac Code	ive Secuts, calls. tion of Se Ac	rities warra	Acquiants, our control of the contro	Persons in this fo displays ired, Dispo options, con 6. Date Exer	orm are not a current sed of, or B vertible sed or and Date	t requ y valid eneficia urities 7. Tof U Sec	uired to it id OMB of	respond control n ned Amount	unless the umber. 8. Price of		f 10. Ownersh Form of	11. Natur of Indire Beneficia
1. Title of Derivative Security	2. Conversion or Exercise Price of	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., pu 4. Transac Code	ive Secutes, calls. 5. tion of Security or of (In	rities warra Numbe Deriva curities quired Dispos	Acquiants, or tive list (A) sed	Persons in this for displays dired, Disposoptions, con 6. Date Exerence Expiration I	orm are not a current sed of, or B vertible sed or and Date	t requ y valid eneficia urities 7. Tof U Sec	ally Own Title and Underlyin curities	respond control n ned Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	f 10. Ownersh Form of Derivativ Security: Direct (E or Indirec s) (I)	11. Natur p of Indire Beneficie Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., pu 4. Transac Code	ive Secuts, calls. 5. tion of Second or of (In and	rities warra Numbe Deriva curities quired Dispos (D) str. 3,	Acquiants, or fitive I is (A) sed	Persons in this for displays dired, Disposoptions, con 6. Date Exerence Expiration I	orm are no a current sed of, or B exertible secretable and obte //Year)	t requ y valid eneficia urities 7. Tof U Sec	ally Own s) Title and Underlyin curities nstr. 3 and	respond control n ned Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownersh Form of Derivativ Security: Direct (D or Indirec	11. Natu p of Indire Benefici e Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
RINGROSE PETER S C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/24/2012
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.